Phase 3 N=1,360 Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
COVID-19
Primary: Number of Participants With Clinical Infection With COVID-19 Infection — 41; 53 Participants — p=0.200
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=360 Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age
Meningococcal Immunisation (Healthy Volunteers)
Primary: Percentage of Participants With Vaccine Seroresponse For Meningococcal Serogroup A, C, Y And W Following Vaccination With MenACYW Conjugate and Menactra® Vaccine…
Phase 3 N=240 Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral Infection
Viral Respiratory Infection
Primary: Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms — 4.1; 5.0 days — p=0.0155
Phase 3 N=707 Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers
Meningococcal Immunisation (Healthy Volunteers)
Primary: Percentage of Participants With Antibody Titers >=1:8 Against Meningococcal Serogroup C Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Following…
Phase 3 N=803 Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine
Infections, Meningococcal
Primary: Percentage of Participants With Serum Bactericidal Assay Using Rabbit Complement Antibody (rSBA) Titers >=1:8 at 1 Month After Administration of 1 Dose of MenACWY-TT in…
Phase 3 N=290 Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections
Necrotizing Soft Tissue Infections · Necrotizing Fasciitis · Fournier's Gangrene
Primary: Number of Patients Achieving Necrotizing Infections Clinical Composite Endpoint (NICCE) — 69; 59; 67; 50 Participants — p=0.135
Phase 3 N=64 A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects
Chronic Hepatitis C Infection
Primary: Part 1: Maximum Plasma Concentration (Cmax) of Ombitasvir (OBV) — 99.6; 116; 83.7 ng/mL
Phase 3 N=251 Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Obstructive Hypertrophic Cardiomyopathy
Primary: Percentage of Participants Achieving A Clinical Response — 45; 22 Participants
Phase 3 N=922 A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis
CKD Anemia
Primary: United States (US FDA) Submission: Mean Change From Baseline in Hb (g/dL) Over Weeks 28 to 52 Regardless of Rescue Therapy — 9.10; 9.09; 2.00; 0.16 g/dL — p=<0.0001
Phase 3 N=1,043 Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants
Anemia in Incident Dialysis Patients
Primary: US (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Week 28 to Week 52), Regardless of Rescue Therapy (ITT Population)…
Phase 3 N=52 Evaluate Use of Caudal Nerve Blocks in Adult Penile Prosthesis
Malignant Neoplasms of Male Genital Organs
Primary: Post-Operative Pain Medication Usage in Post Anesthesia Care Unit (PACU) — 13.0208; 15.1786 mg
Phase 3 N=205 Topical Ibuprofen for Delayed Onset Mulscle Soreness
Pain
Primary: Change From Baseline in the Time-Weighted Sum of Muscle Soreness With Movement Over 0-24 Hours Post-Dose 1 (MSM 0-24 ) — 22.2; 17.8; 29.7 units on a scale — p=0.200
Phase 3 N=477 Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration
Age-related Macular Degeneration (AMD)
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) [Letters] After 8 Weeks — 5.1; 5.6; 5.4 letters
Phase 3 N=118 Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects
Rabies
Primary: The Difference Between KamRAB and HRIG Comparator, in the Proportions of Subjects With Serum Anti-rabies IgG Antibody Concentration ≥ 0.5 IU/mL — 55; 58 Participants
Phase 3 N=2,516 TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens
Tuberculosis
Primary: TB Disease-free Survival at 12M After Study Treatment Assignment Among Participants in Control Regimen, Regimen1 (2HRZE/4HR) to Experimental Regimens, Regimen3…